secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020569
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted
--------------------------------------------------------------------------------

- Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.
- TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% control, 74.4% relative improvement.
- Confirmed ORR 17.5% (7/40) vs 10.3% control, 69.9% relative improvement; 80% TPST-1120 arm on study vs 50% control.
- TPST-1495 enrolling endometrial cancer arm with pembrolizumab; TREX1 inhibitor preclinical data presented at AACR.
- Expects updated TPST-1120 data from Roche; plans to report TPST-1495 data at ASCO 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/tpst-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer